What is ENLV's P/E ratio?

Enlivex Therapeutics LTD (ENLV) currently trades at a P/E ratio of 0.01.

Enlivex Therapeutics LTD reports a Return on Equity (ROE) of 63.85%.

What is ENLV's dividend yield?

Enlivex Therapeutics LTD offers a dividend yield of 0.00%.

What is ENLV's Quality Score?

Our AI rates ENLV's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ENLV?

Our AI Timing Score for ENLV is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ENLV belong to?

Enlivex Therapeutics LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Enlivex Therapeutics LTD (ENLV) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2025-12-31)

ENLV AI Analysis Summary

Our AI summary for ENLV: Enlivex Therapeutics LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.01, ROE of 63.85%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ENLV

Enlivex Therapeutics LTD

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 2.18

0.07 (3.32%) Day Change

Watchlist Portfolio Compare Chart

0.01

P/E

0.00

D/E

63.9%

ROE

53.1%

ROA

0.00%

Div Yield

ENLIVEX THERAPEUTICS LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.18 Price 0.07 (3.32%) Day Change	NEWS SCORE: N/A

ENLV, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.18
PBV / Sector	N/A / 44,105.10
Earning Per Share	382.13

PE / Sector	0.01 / 19.37 GREAT
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	1.01 M GREAT
Average 1W Daily Value	0.70 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	53.10 / 185,260.64 GREAT
ROA Average (%) / Sector	-31.49 / 36,684.64
ROA Change Average (%) / Sector	-52.44 / 422,221.42
ROE (%) / Sector	63.85 / 243,761.81 GREAT
ROE Average (%) / Sector	-37.77 / 48,758.38
ROE Change Average (%) / Sector	-52.54 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:56
Symbol	ENLV
Name	ENLIVEX THERAPEUTICS LTD
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	16.83 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	7.00 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 14 Einstein Street, Ness Ziona, Israel, 7403618

Phone: 972 2 620 8072

Website: https://www.enlivex.com

Sector: Healthcare >> Biotechnology

Description: Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.